165 related articles for article (PubMed ID: 30685248)
1. Costs of herpes zoster complications in older adults: A cohort study of US claims database.
Meyers JL; Candrilli SD; Rausch DA; Yan S; Patterson BJ; Levin MJ
Vaccine; 2019 Feb; 37(9):1235-1244. PubMed ID: 30685248
[TBL] [Abstract][Full Text] [Related]
2. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States.
Meyers JL; Madhwani S; Rausch D; Candrilli SD; Krishnarajah G; Yan S
Hum Vaccin Immunother; 2017 Aug; 13(8):1861-1872. PubMed ID: 28605285
[TBL] [Abstract][Full Text] [Related]
3. Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals.
Meyers JL; Candrilli SD; Rausch DA; Yan S; Patterson BJ; Levin MJ
Vaccine; 2018 Oct; 36(45):6810-6818. PubMed ID: 30249425
[TBL] [Abstract][Full Text] [Related]
4. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.
White RR; Lenhart G; Singhal PK; Insinga RP; Itzler RF; Pellissier JM; Segraves AW
Pharmacoeconomics; 2009; 27(9):781-92. PubMed ID: 19757871
[TBL] [Abstract][Full Text] [Related]
5. Healthcare resource utilization and costs associated with herpes zoster in the US.
Johnson BH; Palmer L; Gatwood J; Lenhart G; Kawai K; Acosta CJ
J Med Econ; 2016 Oct; 19(10):928-35. PubMed ID: 27149530
[TBL] [Abstract][Full Text] [Related]
6. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.
Insinga RP; Itzler RF; Pellissier JM
Pharmacoeconomics; 2007; 25(2):155-69. PubMed ID: 17249857
[TBL] [Abstract][Full Text] [Related]
7. Annual incidence rates of herpes zoster among an immunocompetent population in the United States.
Johnson BH; Palmer L; Gatwood J; Lenhart G; Kawai K; Acosta CJ
BMC Infect Dis; 2015 Nov; 15():502. PubMed ID: 26546419
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
9. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study.
Schmidt-Ott R; Schutter U; Simon J; Nautrup BP; von Krempelhuber A; Gopala K; Anastassopoulou A; Guignard A; Curran D; Matthews S; Espié E
J Infect; 2018 May; 76(5):475-482. PubMed ID: 29428228
[TBL] [Abstract][Full Text] [Related]
10. Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis.
Curran D; Hunjan M; El Ghachi A; El-Hahi Y; Bianco V; Ferreira G
BMJ Open; 2019 Aug; 9(8):e023502. PubMed ID: 31462457
[TBL] [Abstract][Full Text] [Related]
11. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia.
Friesen KJ; Chateau D; Falk J; Alessi-Severini S; Bugden S
BMC Infect Dis; 2017 Jan; 17(1):69. PubMed ID: 28086817
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study.
Gialloreti LE; Merito M; Pezzotti P; Naldi L; Gatti A; Beillat M; Serradell L; di Marzo R; Volpi A
BMC Infect Dis; 2010 Aug; 10():230. PubMed ID: 20682044
[TBL] [Abstract][Full Text] [Related]
13. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction.
Yawn BP; Saddier P; Wollan PC; St Sauver JL; Kurland MJ; Sy LS
Mayo Clin Proc; 2007 Nov; 82(11):1341-9. PubMed ID: 17976353
[TBL] [Abstract][Full Text] [Related]
14. Herpes zoster-attributable resource utilization and cost burden in patients with solid organ transplant.
Palmer L; White RR; Johnson BH; Fowler R; Acosta CJ
Transplantation; 2014 Jun; 97(11):1178-84. PubMed ID: 24892964
[TBL] [Abstract][Full Text] [Related]
15. Herpes zoster burden in patients with asthma: real-world incidence, healthcare resource utilisation and cost.
Singer D; Thompson-Leduc P; Ma S; Gupta D; Cheng WY; Muthukumar A; Devine F; Sundar M; Bogart M; Hagopian E; Poston S; Duh MS; Oppenheimer JJ
BMJ Open Respir Res; 2024 Jun; 11(1):. PubMed ID: 38862238
[TBL] [Abstract][Full Text] [Related]
16. Incidence of herpes zoster and its complications in Germany, 2005-2009.
Hillebrand K; Bricout H; Schulze-Rath R; Schink T; Garbe E
J Infect; 2015 Feb; 70(2):178-86. PubMed ID: 25230396
[TBL] [Abstract][Full Text] [Related]
17. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012.
Yanni EA; Ferreira G; Guennec M; El Hahi Y; El Ghachi A; Haguinet F; Espie E; Bianco V
BMJ Open; 2018 Jun; 8(6):e020528. PubMed ID: 29880565
[TBL] [Abstract][Full Text] [Related]
18. Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy: A retrospective cohort study.
Mao J; McPheeters JT; Finelli L
Medicine (Baltimore); 2017 Dec; 96(48):e8746. PubMed ID: 29310348
[TBL] [Abstract][Full Text] [Related]
19. Economic Burden of Herpes Zoster ("culebrilla") in Latin America.
Rampakakis E; Pollock C; Vujacich C; Toniolo Neto J; Ortiz Covarrubias A; Monsanto H; Johnson KD
Int J Infect Dis; 2017 May; 58():22-26. PubMed ID: 28267595
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Hornberger J; Robertus K
Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
